Ambrisentan

Selective endothelin A receptor antagonist used for managing pulmonary arterial hypertension and improving functional capacity.

Treatment of Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise ability and delay clinical worsening.

Anti-hypertensive, Endothelin receptor antagonist

Selective ETA receptor antagonist

High-affinity ETA receptor antagonist blocking vasoconstriction and cell proliferation mediated by Endothelin-1.

Competitive and selective antagonism of endothelin A receptors in vascular smooth muscle.

Adult dose: Initial treatment is 5 mg once daily, can be increased to 10 mg once daily. Administered with or without food.

Oral administration with or without food.

Take as soon as remembered.

Decreases in hemoglobin concentration, hematocrit, and peripheral edema.

Monitor for fluid retention, pulmonary veno-occlusive disease, hematological changes; avoid in moderate/severe hepatic impairment.

Contraindicated in pregnancy (Category X) and patients with Idiopathic Pulmonary Fibrosis (IPF).

Cyclosporine co-administration increases Ambrisentan exposure; limit dose to 5 mg daily.

Food does not affect its bioavailability.

Pregnancy Category X. Contraindicated in pregnancy.

Pregnancy Category: X — always consult a doctor before taking during pregnancy.

Breastfeeding while receiving Ambrisentan is not recommended.

Safety and effectiveness in pediatric patients have not been established.

Use as advised by physician.

Not recommended in moderate or severe hepatic impairment.

Supportive care as needed.

Store below 30°C, protected from light and moisture.

Ambrisentan